Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02531698
Previous Study | Return to List | Next Study

A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02531698
Recruitment Status : Completed
First Posted : August 24, 2015
Results First Posted : March 27, 2018
Last Update Posted : October 26, 2020
Sponsor:
Information provided by (Responsible Party):
Pfizer

Tracking Information
First Submitted Date  ICMJE August 20, 2015
First Posted Date  ICMJE August 24, 2015
Results First Submitted Date  ICMJE February 28, 2018
Results First Posted Date  ICMJE March 27, 2018
Last Update Posted Date October 26, 2020
Actual Study Start Date  ICMJE August 2015
Actual Primary Completion Date March 2017   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 28, 2018)
  • Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >= Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Neisseria Meningitidis Serogroup B (MnB) Test Strains 1 Month After Vaccination 3 [ Time Frame: 1 month after Vaccination 3 ]
    Percentage of participants achieving hSBA titer >= LLOQ were computed along with corresponding 2-sided 95 percent (%) confidence interval (CIs). LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).
  • Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days After Vaccination 1 [ Time Frame: Within 7 Days after Vaccination 1 ]
    Local reactions included pain at injection site, swelling and redness collected by using an electronic diary (e-diary). Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity) and severe (prevented daily activity). Redness and swelling were graded as: mild (0.5-2.0 centimeter [cm]), moderate (2.5 to 7.0 cm) and severe (>7.0 cm).
  • Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days After Vaccination 2 [ Time Frame: Within 7 Days after Vaccination 2 ]
    Local reactions included pain at injection site, swelling and redness collected by using an e-diary. Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity) and severe (prevented daily activity). Redness and swelling were graded as: mild (0.5-2.0 cm), moderate (2.5 to 7.0 cm) and severe (>7.0 cm).
  • Percentage of Participants Reporting Pre-specified Local Reactions Within 7 Days After Vaccination 3 [ Time Frame: Within 7 Days after Vaccination 3 ]
    Local reactions included pain at injection site, swelling and redness collected by using an e-diary. Pain was graded as: mild (did not interfere with activity), moderate (interfered with activity) and severe (prevented daily activity). Redness and swelling were graded as: mild (0.5-2.0 cm), moderate (2.5 to 7.0 cm) and severe (>7.0 cm).
  • Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Vaccination 1 [ Time Frame: Within 7 Days after Vaccination 1 ]
    Systemic reactions included fever, vomiting, diarrhea, headache, fatigue, muscle and joint pain (other than at the injection site) and recorded by using an e-diary. Fever was graded as 38.0 to 38.4 degree Celsius (C), 38.5 to 38.9 degree C, 39.0 to 39.4 degree C, >39.5 to 40.0 degree C and >40.0 degree C. Vomiting was graded as mild (1-2 times in 24 hours), moderate (>2 times in 24 hours) and severe (required intravenous hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (>=6 loose stools in 24 hours). Headache, fatigue, muscle pain and joint pain were graded as mild (no interference with activity), moderate (some interference with activity) and severe (prevented daily activity).
  • Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Vaccination 2 [ Time Frame: Within 7 Days after Vaccination 2 ]
    Systemic reactions included fever, vomiting, diarrhea, headache, fatigue, muscle and joint pain (other than at the injection site) and recorded by using an e-diary. Fever was graded as 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 39.4 degree C, >39.5 to 40.0 degree C and >40.0 degree C. Vomiting was graded as mild (1-2 times in 24 hours), moderate (>2 times in 24 hours) and severe (required intravenous hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (>=6 loose stools in 24 hours). Headache, fatigue, muscle pain and joint pain were graded as mild (no interference with activity), moderate (some interference with activity) and severe (prevented daily activity).
  • Percentage of Participants Reporting Systemic Events and Antipyretic Use Within 7 Days After Vaccination 3 [ Time Frame: Within 7 Days after Vaccination 3 ]
    Systemic reactions included fever, vomiting, diarrhea, headache, fatigue, muscle and joint pain (other than at the injection site) and recorded by using an e-diary. Fever was graded as 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 39.4 degree C, >39.5 to 40.0 degree C and >40.0 degree C. Vomiting was graded as mild (1-2 times in 24 hours), moderate (>2 times in 24 hours) and severe (required intravenous hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (>=6 loose stools in 24 hours). Headache, fatigue, muscle pain and joint pain were graded as mild (no interference with activity), moderate (some interference with activity) and severe (prevented daily activity).
  • Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Vaccination 1 [ Time Frame: Within 30 Days after Vaccination 1 ]
    SAE was an adverse event (AE) resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.
  • Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Vaccination 2 [ Time Frame: Within 30 Days after Vaccination 2 ]
    SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.
  • Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Vaccination 3 [ Time Frame: Within 30 Days after Vaccination 3 ]
    SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.
  • Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Any Vaccination [ Time Frame: Within 30 Days after any vaccination ]
    SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.
  • Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Vaccination Phase [ Time Frame: From the Vaccination 1 up to 1 month after Vaccination 3 ]
    SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.
  • Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Follow-up Phase [ Time Frame: From 1 month after Vaccination 3 up to 6 months after Vaccination 3 ]
    SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.
  • Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Throughout the Study [ Time Frame: From Vaccination 1 up to 6 months after Vaccination 3 ]
    SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; lack of efficacy in an approved indication. An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.
  • Percentage of Participants With at Least 1 Medically Attended Adverse Event (AE) Within 30 Days After Vaccination 1 [ Time Frame: Within 30 Days after Vaccination 1 ]
    A medically attended AE was defined as a non-serious AE that resulted in an evaluation at a medical facility.
  • Percentage of Participants With at Least 1 Medically Attended Adverse Event (AE) Within 30 Days After Vaccination 2 [ Time Frame: Within 30 Days after Vaccination 2 ]
    A medically attended AE was defined as a non-serious AE that resulted in an evaluation at a medical facility.
  • Percentage of Participants With at Least 1 Medically Attended Adverse Event (AE) Within 30 Days After Vaccination 3 [ Time Frame: Within 30 Days after Vaccination 3 ]
    A medically attended AE was defined as a non-serious AE that resulted in an evaluation at a medical facility.
  • Percentage of Participants With at Least 1 Medically Attended Adverse Event (AE) Within 30 Days After Any Vaccination [ Time Frame: Within 30 Days after any vaccination ]
    A medically attended AE was defined as a non-serious AE that resulted in an evaluation at a medical facility.
  • Percentage of Participants With at Least 1 Medically Attended Adverse Event (AE) During the Vaccination Phase [ Time Frame: From the Vaccination 1 up to 1 month after the Vaccination 3 ]
    A medically attended AE was defined as a non-serious AE that resulted in an evaluation at a medical facility.
  • Percentage of Participants With at Least 1 Medically Attended Adverse Event (AE) During the Follow-up Phase [ Time Frame: From 1 month after Vaccination 3 up to 6 months after the Vaccination 3 ]
    A medically attended AE was defined as a non-serious AE that resulted in an evaluation at a medical facility.
  • Percentage of Participants With at Least 1 Medically Attended Adverse Event (AE) Throughout the Study [ Time Frame: From the Vaccination 1 up to 6 months after the Vaccination 3 ]
    A medically attended AE was defined as a non-serious AE that resulted in an evaluation at a medical facility.
  • Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Vaccination 1 [ Time Frame: Within 30 Days after Vaccination 1 ]
    A newly diagnosed chronic medical condition was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.
  • Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Vaccination 2 [ Time Frame: Within 30 Days after Vaccination 2 ]
    A newly diagnosed chronic medical condition was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.
  • Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Vaccination 3 [ Time Frame: Within 30 Days after Vaccination 3 ]
    A newly diagnosed chronic medical condition was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.
  • Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Any Vaccination [ Time Frame: Within 30 Days after any vaccination ]
    A newly diagnosed chronic medical condition was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.
  • Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Vaccination Phase [ Time Frame: From the Vaccination 1 up to 1 month after the Vaccination 3 ]
    A newly diagnosed chronic medical condition was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.
  • Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Follow-up Phase [ Time Frame: From 1 month after Vaccination 3 up to 6 months after the Vaccination 3 ]
    A newly diagnosed chronic medical condition was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.
  • Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Throughout the Study [ Time Frame: From the Vaccination 1 up to 6 months after the Vaccination 3 ]
    A newly diagnosed chronic medical condition was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.
  • Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Vaccination 1 [ Time Frame: Within 30 Days after Vaccination 1 ]
    AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
  • Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Vaccination 2 [ Time Frame: Within 30 Days after Vaccination 2 ]
    AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
  • Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Vaccination 3 [ Time Frame: Within 30 Days after Vaccination 3 ]
    AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
  • Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Any Vaccination [ Time Frame: Within 30 Days after any vaccination ]
    AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
  • Percentage of Participants With at Least 1 Adverse Event (AE) During the Vaccination Phase [ Time Frame: From the Vaccination 1 up to 1 month after the Vaccination 3 ]
    AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
  • Percentage of Participants With at Least 1 Immediate Adverse Event (AE) After Vaccination 1 [ Time Frame: Within 30 minutes after Vaccination 1 ]
    Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration.
  • Percentage of Participants With at Least 1 Immediate Adverse Event (AE) After Vaccination 2 [ Time Frame: Within 30 minutes after Vaccination 2 ]
    Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration.
  • Percentage of Participants With at Least 1 Immediate Adverse Event (AE) After Vaccination 3 [ Time Frame: Within 30 minutes after Vaccination 3 ]
    Immediate AE was defined as AEs occurring within the first 30 minutes after investigational product administration.
  • Number of Days Participant's Missed School Due to Adverse Event (AE) During the Vaccination Phase [ Time Frame: From the Vaccination 1 up to 1 month after the Vaccination 3 ]
Original Primary Outcome Measures  ICMJE
 (submitted: August 20, 2015)
  • Proportion of subjects with antibody titers ≥lower limit of quantitation for each of the 4 primary Neisseria meningitidis serogroup B test strains 1 month after the third vaccination with bivalent rLP2086 [ Time Frame: Month 7 ]
  • Percentage of subjects reporting local reactions, systemic events and antipyretic use for 7 days after each vaccination visit [ Time Frame: Month 0 ]
  • Percentage of subjects reporting local reactions, systemic events and antipyretic use for 7 days after each vaccination visit [ Time Frame: Month 2 ]
  • Percentage of subjects reporting local reactions, systemic events and antipyretic use for 7 days after each vaccination visit [ Time Frame: Month 6 ]
  • Percentage of subjects with at least 1 SAE 30 days after each vaccination, 30 days after any vaccination, during the vaccination phase, during the follow-up phase, and throughout the study period [ Time Frame: Up to 12 months ]
  • Percentage of subjects with at least 1 medically attended adverse event 30 days after each vaccination, 30 days after any vaccination, during the vaccination phase, during the follow-up phase, and throughout the study period [ Time Frame: Up to 12 months ]
  • Percentage of subjects with at least 1 newly diagnosed chronic medical condition 30 days after each vaccination, 30 days after any vaccination, during the vaccination phase, during the follow-up phase, and throughout the study period [ Time Frame: Up to 12 months ]
  • Percentage of subjects with at least 1 adverse event 30 days after each vaccination, 30 days after any vaccination and during the vaccination phase [ Time Frame: Up to 7 months ]
  • Percentage of subjects reporting at least 1 immediate AE after each vaccination [ Time Frame: Month 0 ]
  • Percentage of subjects reporting at least 1 immediate AE after each vaccination [ Time Frame: Month 2 ]
  • Percentage of subjects reporting at least 1 immediate AE after each vaccination [ Time Frame: Month 6 ]
  • Subject's days missing school due to AEs during the vaccination phase [ Time Frame: Up to 7 months ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 28, 2018)
  • Percentage of Participants Aged >=24 Months to <10 Years With hSBA Titer >= LLOQ for Each of the 4 Primary MnB Test Strains 1 Month After Vaccination 3 [ Time Frame: 1 month after Vaccination 3 ]
    Percentage of participants achieving hSBA titer >= LLOQ were computed along with corresponding 2-sided 95% CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).
  • Percentage of Participants With hSBA Titer >= LLOQ for Each of the 4 Primary MnB Test Strains 1 Month After Vaccination 2 and 6 Months After Vaccination 3 [ Time Frame: 1 month after Vaccination 2 and 6 months after Vaccination 3 ]
    Percentage of participants achieving hSBA titer >= LLOQ were computed along with corresponding 2-sided 95% CIs. LLOQ was 1:16 for PMB80 (A22) and 1:8 for PMB2001 (A56), PMB2948 (B24), and PMB2707 (B44).
  • Percentage of Participants With Serum Bactericidal Assay Using hSBA Titers >=1:4, >=1:8, >=1:16, >=1:32, >=1:64 and >=1:128 for Each of the 4 Primary Test Strains [ Time Frame: Before Vaccination 1, 1 month after Vaccination 2, 1 month after Vaccination 3 and 6 months after Vaccination 3 ]
  • Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs) for Each of the 4 Primary Test Strains [ Time Frame: Before Vaccination 1, 1 month after Vaccination 2, 1 month after Vaccination 3 and 6 months after Vaccination 3 ]
Original Secondary Outcome Measures  ICMJE
 (submitted: August 20, 2015)
  • Proportion of subjects with antibody titers ≥lower limit of quantitation for each of the 4 primary Neisseria meningitidis serogroup B test strains 1 month after the second vaccination and 1 and 6 months after the third vaccination with bivalent rLP2086 [ Time Frame: Up to 12 months ]
  • Proportion of subjects achieving fold rises in antibody titers for each of the 4 primary test strains at baseline, 1 month after the second vaccination, and 1 and 6 months after the third vaccination with bivalent rLP2086 [ Time Frame: Up to 12 months ]
  • Geometric mean antibody titers for each of the 4 primary test strains at baseline, 1 month after the second vaccination, and 1 and 6 months after the third vaccination with bivalent rLP2086 [ Time Frame: Up to 12 months ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years
Official Title  ICMJE A Phase 2, Randomized, Controlled, Observer-blinded Study To Describe The Immunogenicity, Safety, And Tolerability Of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent Rlp2086) In Healthy Subjects Aged >/= 24 Months To <10 Years
Brief Summary This study is looking at a new vaccine that might prevent meningococcal disease, and will study the immune response elicited by this vaccine when given to healthy young children. The study will also look at the safety of the new vaccine as well as how it is tolerated.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Condition  ICMJE MENINGOCOCCAL INFECTION
Intervention  ICMJE
  • Biological: Bivalent rLP2086 Vaccine
    1 dose of 120 μg of bivalent rLP2086 by intramuscular injection at Months 0, 2, and 6 into the upper deltoid muscle of the arm.
  • Biological: Licensed pediatric hepatits A vaccine
    1 0.5 mL dose by intramuscular injection at Months 0 and 6 into the upper deltoid muscle of the arm.
  • Other: Normal Saline
    Sterile saline solution for injection (0.85% sodium chloride) in a 0.5 mL dose at Month 2.
Study Arms  ICMJE
  • Experimental: Bivalent rLP2086
    Bivalent rLP2086 (containing 60 μg each of a purified subfamily A and subfamily B rLP2086 protein, adsorbed to aluminum in a sterile buffered isotonic suspension) in a 0.5-mL dose for injection.
    Intervention: Biological: Bivalent rLP2086 Vaccine
  • Licensed pediatric hepatitis A vaccine
    Interventions:
    • Biological: Licensed pediatric hepatits A vaccine
    • Other: Normal Saline
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: August 20, 2015)
400
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE March 2017
Actual Primary Completion Date March 2017   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Evidence of a personally signed and dated informed consent document (ICD) indicating that the subject's parent(s)/legal guardian has been informed of all pertinent aspects of the study.
  2. Parent(s)/legal guardian and subject who are willing and able to comply with scheduled visits, vaccine regimen, laboratory tests, and other study procedures.
  3. Male or female subjects aged ≥24 months and <10 years at time of randomization, stratified equally by age (≥24 months to <4 years or ≥4 years to <10 years).
  4. Subject is available for the entire study period and subject's parent(s)/legal guardian can be reached by telephone.
  5. Healthy subject as determined by medical history, physical examination, and judgment of the investigator.
  6. Subject must have received all vaccinations in the relevant national immunization program (NIP) for their age group.
  7. Male and female subjects of childbearing potential and at risk for pregnancy must agree to use a highly effective method of contraception throughout the study. A subject is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active.
  8. Negative urine pregnancy test for all female subjects who are biologically capable of having children.

Exclusion Criteria:

  1. Previous vaccination with any meningococcal serogroup B vaccine.
  2. Subjects who have received prior HAV vaccination.
  3. Contraindication to vaccination with any HAV vaccine or known latex allergy.
  4. Subjects receiving any allergen immunotherapy with a nonlicensed product or subjects receiving allergen immunotherapy with a licensed product and who are not on stable maintenance doses.
  5. A previous anaphylactic reaction to any vaccine or vaccine-related component.
  6. Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
  7. A known or suspected defect of the immune system that would prevent an immune response to the vaccine, such as subjects with congenital or acquired defects in B-cell function, those receiving chronic systemic (oral, intravenous, or intramuscular) corticosteroid therapy, or those receiving immunosuppressive therapy. Subjects with terminal complement deficiency may be included. Additional details will be provided in the study reference manual (SRM).
  8. History of microbiologically proven disease caused by N meningitidis or Neisseria gonorrhoeae.
  9. Significant neurological disorder or history of seizure (excluding simple febrile seizure).
  10. Receipt of any blood products, including immunoglobulin, within 6 months before the first study vaccination.
  11. Current chronic use of systemic antibiotics.
  12. Participation in other studies involving investigational product(s)/device(s) (Phases 1-4) within 28 days before administration of the first study vaccination. Participation in purely observational studies is acceptable.
  13. Any neuroinflammatory or autoimmune condition, including but not limited to transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.
  14. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  15. Pregnant female subjects, breastfeeding female subjects, male subjects with partners who are currently pregnant, or male and female subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study.
  16. Subjects who are children of investigational site staff members directly involved in the conduct of the study and their family members, subjects who are children of site staff members otherwise supervised by the investigator, or subjects who are children of Pfizer employees directly involved in the conduct of the study.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 24 Months to 10 Years   (Child)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Finland,   Poland
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02531698
Other Study ID Numbers  ICMJE B1971017
2014-000933-21 ( EudraCT Number )
6108K2-3012 ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Pfizer CT.gov Call Center Pfizer
PRS Account Pfizer
Verification Date October 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP